sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 1 of 28
AHFS Category: 80:12 IPV 1
Poliovirus Vaccine Inactivated
IPOL
®
DESCRIPTION 2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
IPOL®, Poliovirus Vaccine Inactivated, produced by Sanofi Pasteur SA, is a sterile suspension of
three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). IPOL
vaccine is a highly purified, inactivated poliovirus vaccine with enhanced potency. Each of the
three strains of poliovirus is individually grown in vero cells, a continuous line of monkey kidney
cells cultivated on microcarriers. (1) (2) The cells are grown in Eagle MEM modified medium,
supplemented with newborn calf serum tested for adventitious agents prior to use, originated from
countries free of bovine spongiform encephalopathy. For viral growth the culture medium is
replaced by M-199, without calf serum. This culture technique and improvements in purification,
concentration, and standardization of poliovirus antigen produce a more potent and consistent
immunogenic vaccine than the inactivated poliovirus vaccine (IPV) available in the US prior to
1988. (3) (4)
After clarification and filtration, viral suspensions are concentrated by ultrafiltration, and purified
by three liquid chromatography steps; one column of anion exchanger, one column of gel
filtration, and again one column of anion exchanger. After re-equilibration of the purified viral
suspension, with Medium M-199 and adjustment of the antigen titer, the monovalent viral
suspensions are inactivated at +37°C for at least 12 days with 1:4000 formalin.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 2 of 28
Each dose (0.5 mL) of trivalent vaccine is formulated to contain 40 D antigen units of Type 1, 8 D
antigen units of Type 2, and 32 D antigen units of Type 3 poliovirus. For each lot of IPOL
vaccine, D-antigen content is determined in vitro using the D-antigen ELISA assay. IPOL vaccine
is produced from vaccine concentrates diluted with M-199 medium. Also present are 0.5% of 2-
phenoxyethanol and a maximum of 0.02% of formaldehyde per dose as preservatives. Neomycin,
streptomycin, and polymyxin B are used in vaccine production; and, although purification
procedures eliminate measurable amounts, less than 5 ng neomycin, 200 ng streptomycin, and 25
ng polymyxin B per dose may still be present. The residual calf serum protein is less than 1 ppm
in the final vaccine.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
The vaccine is clear and colorless and should be administered intramuscularly or subcutaneously.
There is no latex in any component of the vial or syringe.
CLINICAL PHARMACOLOGY
Poliomyelitis is caused by poliovirus Types 1, 2, or 3. It is primarily spread by the fecal-oral route
of transmission but may also be spread by the pharyngeal route.
Approximately 90% to 95% of poliovirus infections are asymptomatic. Nonspecific illness with
low-grade fever and sore throat (minor illness) occurs in 4% to 8% of infections. Aseptic
meningitis occurs in 1% to 5% of patients a few days after the minor illness has resolved. Rapid
onset of asymmetric acute flaccid paralysis occurs in 0.1% to 2% of infections, and residual
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 3 of 28
paralytic disease involving motor neurons (paralytic poliomyelitis) occurs in approximately 1 per
1,000 infections.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
(5)
Prior to the introduction of inactivated poliovirus vaccines in 1955, large outbreaks of
poliomyelitis occurred each year in the United States (US). The annual incidence of paralytic
disease of 11.4 cases/100,000 population declined to 0.5 cases by the time oral poliovirus vaccine
(OPV) was introduced in 1961. Incidence continued to decline thereafter to a rate of 0.002 to
0.005 cases per 100,000 population. Of the 127 cases of paralytic poliomyelitis reported in the US
between 1980 and 1994, six were imported cases (caused by wild polioviruses), two were
“indeterminate” cases, and 119 were vaccine associated paralytic poliomyelitis (VAPP) cases
associated with the use of live, attenuated oral poliovirus vaccine (OPV). (6) An all IPV schedule
was adopted in 1999, to eliminate VAPP cases. (7)
Poliovirus Vaccine Inactivated induces the production of neutralizing antibodies against each type
of virus which are related to protective efficacy. Antibody response in most children were induced
after receiving fewer doses (8) of IPV vaccine than the vaccine available in the United States prior
to 1988.
Studies in developed (8) and developing (9), (10) countries with a similar enhanced IPV
manufactured by the same process as IPOL vaccine in primary monkey kidney cells have shown a
direct relationship exists between the antigenic content of the vaccine, the frequency of
seroconversion, and resulting antibody titer. Approval in the US was based upon demonstration of
immunogenicity and safety in US children. (11)
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 4 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
In the US, 219 infants received three doses of a similar enhanced IPV at two, four, and eighteen
months of age manufactured by the same process as IPOL vaccine except the cell substrate for
IPV was using primary monkey kidney cells. Seroconversion to all three types of poliovirus was
demonstrated in 99% of these infants after two doses of vaccine given at 2 and 4 months of age.
Following the third dose of vaccine at 18 months of age, neutralizing antibodies were present at a
level of ≥1:10 in 99.1% of children to Type 1 and 100% of children to Types 2 and 3 polioviruses.
(3)
IPOL vaccine was administered to more than 700 infants between 2 to 18 months of age during
three clinical studies conducted in the US using IPV only schedules and sequential IPV-OPV
schedules. (12) (13) Seroprevalence rates for detectable serum neutralizing antibody (DA) at a
≥1:4 dilution were 95% to 100% (Type 1); 97% to 100% (Type 2) and 96% to 100% (Type 3)
after two doses of IPOL vaccine depending on studies.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 5 of 28
Table 1: US Studies with IPOL Vaccine Administered Using IPV Only or Sequential IPV-
OPV Schedules
1
2
Age (months) for
2 4 6 12 to 18
Dose 1 Dose 2 Dose3 Booster
Post Dose 2
Type 1 Type 2 Type 3
N* %DA** %DA %DA
Post Dose 3
Type 1 Type 2 Type 3
N* %DA %DA %DA
Pre Booster
Type 1 Type 2 Type 3
N* %DA %DA %DA
Post Booster
Type 1 Type 2 Type 3
N* % DA %DA %DA
STUDY 1 (11)
¶
I(s) I(s) NA† I(s)
O O NA O
I(s) O NA O
I(s) I(s) NA O
56 97 100 97
22 100 100 100
17 95 100 95
17 100 100 100
– – –
– – –
– – –
– – –
53 91 97 93
22 78 91 78
17 95 100 95
16 100 100 94
53 97 100 100
20 100 100 100
17 100 100 100
16 100 100 100
STUDY 2 (10) §
I(c) I(c) NA I(s)
I(s) I(s) NA I(s)
I(c) I(c) NA O
I(s) I(s) NA O
94 98 97 96
68 99 100 99
75 95 99 96
101 99 99 95
– – –
– – –
– – –
– – –
100 92 95 88
72 100 100 94
77 86 97 82
103 99 97 89
97 100 100 100
75 100 100 100
78 100 100 97
107 100 100 100
STUDY 3 (10)
§
I(c) I(c) I(c) O
I(c) I(c) O O
I(c) I(c) I(c) + O O
91 98 99 100
96 100 98 99
91 96 97 100
91 100 100 100
94 100 100 99
85 100 100 100
41 100 100 100
47 100 100 100
47 100 100 100
40 100 100 100
45 100 100 100
46 100 100 100
* N = Number of children from whom serum was available 3
4
5
6
7
8
9
10
11
** Detectable antibody (neutralizing titer ≥1:4)
† NA – No poliovirus vaccine administered
¶ IPOL vaccine given subcutaneously
§ IPOL vaccine given intramuscularly
I IPOL vaccine given either separately in association with DTP in two sites (s) or combined (c) with DTP in a
dual chambered syringe
O OPV
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 6 of 28
In one study, (13) the persistence of DA in infants receiving two doses of IPOL vaccine at 2 and 4
months of age was 91% to 100% (Type 1), 97% to 100% (Type 2), and 93% to 94% (Type 3) at
twelve months of age. In another study,
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
(12) 86% to 100% (Type 1), 95% to 100% (Type 2), and
82% to 94% (Type 3) of infants still had DA at 18 months of age.
In trials and field studies conducted outside the US, IPOL vaccine, or a combination vaccine
containing IPOL vaccine and DTP, was administered to more than 3,000 infants between 2 to 18
months of age using IPV only schedules and immunogenicity data are available from 1,485
infants. After two doses of vaccine given during the first year of life, seroprevalence rates for
detectable serum neutralizing antibody (neutralizing titer ≥1:4) were 88% to 100% (Type 1); 84%
to 100% (Type 2) and 94% to 100% (Type 3) of infants, depending on studies. When three doses
were given during the first year of life, post-dose 3 DA ranged between 93% to 100% (Type 1);
89% to 100% (Type 2) and 97% to 100% (Type 3) and reached 100% for Types 1, 2, and 3 after
the fourth dose given during the second year of life (12 to 18 months of age). (14)
In infants immunized with three doses of an unlicensed combination vaccine containing IPOL
vaccine and DTP given during the first year of life, and a fourth dose given during the second year
of life, the persistence of detectable neutralizing antibodies was 96%, 96%, and 97% against
poliovirus Types 1, 2, and 3, respectively, at six years of age. DA reached 100% for all types after
a booster dose of IPOL vaccine combined with DTP vaccine. (11) A survey of Swedish children
and young adults given a Swedish IPV only schedule demonstrated persistence of detectable
serum neutralizing antibody for at least 10 years to all three types of poliovirus. (15)
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 7 of 28
IPV is able to induce secretory antibody (IgA) produced in the pharynx and gut and reduces
pharyngeal excretion of poliovirus Type 1 from 75% in children with neutralizing antibodies at
levels less than 1:8 to 25% in children with neutralizing antibodies at levels more than 1:64.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
(4)
(14) (16) (17) (18) (19) (20) (21) (22) There is also evidence of induction of herd immunity with
IPV, (15) (23) (24) (25) (26) and that this herd immunity is sufficiently maintained in a population
vaccinated only with IPV. (26)
VAPP has not been reported in association with administration of IPOL vaccine. (27) It is
expected that an IPV only schedule will eliminate the risk of VAPP in both recipients and
contacts compared to a schedule that included OPV. (7)
INDICATIONS AND USAGE IPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age),
children, and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3.
(28)
INFANTS, CHILDREN AND ADOLESCENTS
General Recommendations
It is recommended that all infants (as young as 6 weeks of age), unimmunized children, and
adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis.
(29) Following the eradication of poliomyelitis caused by wild poliovirus from the Western
Hemisphere (including North and South America) (30), an IPV-only schedule was recommended
to eliminate VAPP. (7)
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 8 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
All children should receive four doses of IPV at ages 2, 4, 6 to 18 months, and 4 to 6 years. OPV
is no longer available in the US and is not recommended for routine immunization. (7)
Previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete
immunization with OPV are not contraindications to completing the primary series of
immunization with IPOL vaccine.
Children Incompletely Immunized
Children of all ages should have their immunization status reviewed and be considered for
supplemental immunization as follows for adults. Time intervals between doses longer than those
recommended for routine primary immunization do not necessitate additional doses as long as a
final total of four doses is reached (see DOSAGE AND ADMINISTRATION section).
ADULTS
General Recommendations
Routine primary poliovirus vaccination of adults (generally those 18 years of age or older)
residing in the US is not recommended. Unimmunized adults who are potentially exposed to wild
poliovirus and have not been adequately immunized should receive polio vaccination in
accordance with the schedule given in the DOSAGE AND ADMINISTRATION section. (28)
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 9 of 28
Persons with previous wild poliovirus disease who are incompletely immunized or unimmunized
should be given additional doses of IPOL vaccine if they fall into one or more categories listed
previously.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
The following categories of adults are at an increased risk of exposure to wild polioviruses: (28)
(31)
• Travelers to regions or countries where poliomyelitis is endemic or epidemic.
• Health-care workers in close contact with patients who may be excreting polioviruses.
• Laboratory workers handling specimens that may contain polioviruses.
• Members of communities or specific population groups with disease caused by wild
polioviruses.
IMMUNODEFICIENCY AND ALTERED IMMUNE STATUS
IPOL vaccine should be used in all patients with immunodeficiency diseases and members of
such patients’ households when vaccination of such persons is indicated. This includes patients
with asymptomatic HIV infection, AIDS or AIDS-Related Complex, severe combined
immunodeficiency, hypogammaglobulinemia, or agammaglobulinemia; altered immune states due
to diseases such as leukemia, lymphoma, or generalized malignancy; or an immune system
compromised by treatment with corticosteroids, alkylating drugs, antimetabolites or radiation.
Immunogenicity of IPOL vaccine in individuals receiving immunoglobulin could be impaired,
and patients with an altered immune state may or may not develop a protective response against
paralytic poliomyelitis after administration of IPV. (32)
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 10 of 28
As with any vaccine, vaccination with IPOL vaccine may not protect 100% of individuals. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Use with other vaccines: refer to DOSAGE AND ADMINISTRATION section for this
information.
CONTRAINDICATIONS IPOL vaccine is contraindicated in persons with a history of hypersensitivity to any component of
the vaccine, including 2-phenoxyethanol, formaldehyde, neomycin, streptomycin, and polymyxin
B.
No further doses should be given if anaphylaxis or anaphylactic shock occurs within 24 hours of
administration of one dose of vaccine.
Vaccination of persons with an acute, febrile illness should be deferred until after recovery;
however, minor illness, such as mild upper respiratory infection, with or without low grade fever,
are not reasons for postponing vaccine administration.
WARNINGS Neomycin, streptomycin, polymyxin B, 2-phenoxyethanol, and formaldehyde are used in the
production of this vaccine. Although purification procedures eliminate measurable amounts of
these substances, traces may be present (see DESCRIPTION section), and allergic reactions may
occur in persons sensitive to these substances (see CONTRAINDICATIONS section).
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 11 of 28
Systemic adverse reactions reported in infants receiving IPV concomitantly at separate sites or
combined with DTP have been similar to those associated with administration of DTP alone.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
(11)
Local reactions are usually mild and transient in nature.
Although no causal relationship between IPOL vaccine and Guillain-Barré Syndrome (GBS) has
been established, (28) GBS has been temporally related to administration of another inactivated
poliovirus vaccine. Deaths have been reported in temporal association with the administration of
IPV (see ADVERSE REACTIONS section).
PRECAUTIONS GENERAL
Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse
reactions. This includes a review of the patient’s history with respect to possible sensitivity to the
vaccine or similar vaccines.
Health-care providers should question the patient, parent or guardian about reactions to a previous
dose of this product, or similar product.
Epinephrine injection (1:1000) and other appropriate agents should be available to control
immediate allergic reactions.
Health-care providers should obtain the previous immunization history of the vaccinee, and
inquire about the current health status of the vaccinee.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 12 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Immunodeficient patients or patients under immunosuppressive therapy may not develop a
protective immune response against paralytic poliomyelitis after administration of IPV.
Administration of IPOL vaccine is not contraindicated in individuals infected with HIV. (33) (34)
(35)
Special care should be taken to ensure that the injection does not enter a blood vessel.
INFORMATION FOR PATIENTS
Patients, parents, or guardians should be instructed to report any serious adverse reactions to their
health-care provider.
The health-care provider should inform the patient, parent, or guardian of the benefits and risks of
the vaccine.
The health-care provider should inform the patient, parent, or guardian of the importance of
completing the immunization series.
The health-care provider should provide the Vaccine Information Statements (VISs) which are
required to be given with each immunization.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 13 of 28
DRUG INTERACTIONS 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
There are no known interactions of IPOL vaccine with drugs or foods. Concomitant
administration of other parenteral vaccines, with separate syringes at separate sites, is not
contraindicated. The first two doses of IPOL vaccine may be administered at separate sites using
separate syringes concomitantly with DTaP, acellular pertussis, Haemophilus influenzae type b
(Hib), and hepatitis B vaccines. From historical data on the antibody responses to diphtheria,
tetanus, acellular pertussis, Hib, or hepatitis B vaccines used concomitantly or in combination
with IPOL vaccine, no interferences have been observed on the immunological end points
accepted for clinical protection. (11) (16) (36) (See DOSAGE AND ADMINISTRATION
section.)
If IPOL vaccine has been administered to persons receiving immunosuppressive therapy, an
adequate immunologic response may not be obtained. (See PRECAUTIONS – GENERAL
section.)
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
Long-term studies in animals to evaluate carcinogenic potential or impairment of fertility have not
been conducted.
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with IPOL vaccine. It is also not known
whether IPOL vaccine can cause fetal harm when administered to a pregnant woman or can affect
reproduction capacity. IPOL vaccine should be given to a pregnant woman only if clearly needed.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 14 of 28
NURSING MOTHERS 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
It is not known whether IPOL vaccine is excreted in human milk. Because many drugs are
excreted in human milk, caution should be exercised when IPOL vaccine is administered to a
nursing woman.
PEDIATRIC USE
SAFETY AND EFFECTIVENESS OF IPOL VACCINE IN INFANTS BELOW SIX WEEKS OF
AGE HAVE NOT BEEN ESTABLISHED. (12) (20) (See DOSAGE AND ADMINISTRATION
section.)
In the US, infants receiving two doses of IPV at 2 and 4 months of age, the seroprevalence to all
three types of poliovirus was demonstrated in 95% to 100% of these infants after two doses of
vaccine. (12) (13)
ADVERSE REACTIONS Body System As A Whole
In earlier studies with the vaccine grown in primary monkey kidney cells, transient local reactions
at the site of injection were observed. (3) Erythema, induration and pain occurred in 3.2%, 1%
and 13%, respectively, of vaccinees within 48 hours post-vaccination. Temperatures of ≥39°C
(≥102°F) were reported in 38% of vaccinees. Other symptoms included irritability, sleepiness,
fussiness, and crying. Because IPV was given in a different site but concurrently with Diphtheria
and Tetanus Toxoids and Pertussis Vaccine Adsorbed (DTP), these systemic reactions could not
be attributed to a specific vaccine. However, these systemic reactions were comparable in
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 15 of 28
frequency and severity to that reported for DTP given alone without IPV. (12) Although no causal
relationship has been established, deaths have occurred in temporal association after vaccination
1
2
3
4
5
6
7
8
of infants with IPV. (37)
Four additional US studies using IPOL vaccine in more than 1,300 infants, (12) between 2 to 18
months of age administered with DTP at the same time at separate sites or combined have
demonstrated that local and systemic reactions were similar when DTP was given alone.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 16 of 28
Table 2 (12): Percentage of Infants Presenting with Local or Systemic Reactions at 6, 24,
and 48 Hours of Immunization with IPOL Vaccine Administered Intramuscularly
Concomitantly at Separate Sites with Sanofi¶ Whole-Cell DTP Vaccine at 2 and 4 Months of
Age and with Sanofi Acellular Pertussis Vaccine (Tripedia®) at 18 Months of Age
1
2
3
4
AGE AT IMMUNIZATION
REACTION
2 Months
(n=211)
6 Hrs. 24 Hrs. 48 Hrs.
4 Months
(n=206)
6 Hrs. 24 Hrs. 48 Hrs.
18 Months†
(n=74)
6 Hrs. 24 Hrs. 48 Hrs.
Local, IPOL vaccine alone§
Erythema >1" Swelling Tenderness
0.5% 0.5% 0.5% 11.4% 5.7% 0.9% 29.4% 8.5% 2.8%
1.0% 0.0% 0.0%
11.2% 4.9% 1.9% 22.8% 4.4% 1.0%
1.4% 0.0% 0.0% 2.7% 0.0% 0.0% 13.5% 4.1% 0.0%
1.0% 0.5% 0.5% 64.5% 24.6% 17.5% 60.7% 31.8% 7.1% 16.6% 8.1% 4.3% 1.9% 2.8% 2.8%
2.0% 0.5% 0.0%
49.5% 25.7% 11.7% 38.8% 18.4% 6.3% 6.3% 4.4% 2.4% 1.9% 1.5% 1.0%
0.0% 0.0% 4.2% 14.7% 6.7% 8.0% 9.3% 5.3% 4.0% 2.7% 1.3% 2.7% 1.3% 1.3% 0.0%
Systemic* Fever >102.2°F Irritability Tiredness Anorexia Vomiting
Persistent Crying Percentage of infants within 72 hours after immunization was 0.0% after dose one, 1.4% after dose two, and 0.0% after dose three.
¶ Sanofi Pasteur Inc. formerly known as Aventis Pasteur Inc. 5
6
7
8
9
§ Data are from the IPOL vaccine administration site, given intramuscularly.
* The adverse reaction profile includes the concomitant use of Sanofi whole-cell DTP vaccine or Tripedia vaccine
with IPOL vaccine. Rates are comparable in frequency and severity to that reported for whole-cell DTP given alone.
† Children who have been vaccinated with Tripedia vaccine.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 17 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Digestive System
Anorexia and vomiting occurred with frequencies not significantly different as reported when
DTP was given alone without IPV or OPV. (12)
Nervous System
Although no causal relationship between IPOL vaccine and GBS has been established, (28) GBS
has been temporally related to administration of another inactivated poliovirus vaccine.
Post-marketing Experience
The following adverse events have been identified during postapproval use of IPOL vaccine.
Because these events are reported voluntarily from a population of uncertain size, it may not be
possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.
Adverse events were included based on one or more of the following factors: severity, frequency
of reporting or strength of evidence for a causal relationship
Blood and lymphatic system disorders: lymphadenopathy
General disorders and administration site conditions: agitation, injection site reaction
including injection site rash and mass
Immune system disorders: type I hypersensitivity including allergic reaction, anaphylactic
reaction, and anaphylactic shock
Musculoskeletal and connective tissue disorders: arthralgia, myalgia
Nervous system disorders: convulsion, febrile convulsion, headache, paresthesia, and
somnolence
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 18 of 28
Skin and subcutaneous tissue disorders: rash, urticaria 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Reporting of Adverse Events
The National Vaccine Injury Compensation Program, established by the National Childhood
Vaccine Injury Act of 1986, requires physicians and other health-care providers who administer
vaccines to maintain permanent vaccination records and to report occurrences of certain adverse
events to the US Department of Health and Human Services. Reportable events include those
listed in the Act for each vaccine and events specified in the package insert as contraindications to
further doses of that vaccine. (38) (39) (40)
Reporting by parents or guardians of all adverse events after vaccine administration should be
encouraged. Adverse events following immunization with vaccine should be reported by health-
care providers to the US Department of Health and Human Services (DHHS) Vaccine Adverse
Event Reporting System (VAERS). Reporting forms and information about reporting
requirements or completion of the form can be obtained from VAERS through a toll-free number
1-800-822-7967. (38) (39) (40)
Health-care providers also should report these events to the Pharmacovigilance
Department, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-
2463.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 19 of 28
DOSAGE AND ADMINISTRATION 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Parenteral drug products should be inspected visually for particulate matter and discoloration
prior to administration, whenever solution and container permit. The syringe or vial and its
packaging should be inspected prior to use for evidence of leakage, premature activation of the
plunger, or a faulty tip seal. If evidence of such defects are observed, the vaccine should not be
used. Do not remove the vial stopper or the metal seal holding it in place.
After preparation of the injection site, using a suitable sterile needle and aseptic technique,
immediately administer IPOL vaccine intramuscularly or subcutaneously. In infants and small
children, the mid-lateral aspect of the thigh is the preferred site. In older children and adults, IPOL
vaccine should be administered intramuscularly or subcutaneously in the deltoid area. IPOL
should not be combined through reconstitution or mixed with any other vaccine.
The pre-filled syringe is intended for single use only, must not be reused, and must be disposed of
properly and promptly following its use.
To help avoid HIV (AIDS), HBV (Hepatitis), and other infectious diseases due to accidental
needlesticks, contaminated needles should not be recapped or removed, unless there is no
alternative or that such action is required by a specific medical procedure.
Care should be taken to avoid administering the injection into or near blood vessels and nerves. If
blood or any suspicious discoloration appears in the syringe, do not inject but discard contents and
repeat procedures using a new dose of vaccine administered at a different site.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 20 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
DO NOT ADMINISTER VACCINE INTRAVENOUSLY.
Children
The primary series of IPOL vaccine consists of three 0.5 mL doses administered intramuscularly
or subcutaneously, preferably eight or more weeks apart and usually at ages 2, 4, and 6 to 18
months. Under no circumstances should the vaccine be given more frequently than four weeks
apart. The first immunization may be administered as early as six weeks of age. For this series, a
booster dose of IPOL vaccine is administered at 4 to 6 years of age. (41)
Use with Other Vaccines
From historical data on the antibody responses to diphtheria, tetanus, whole-cell or acellular
pertussis, Hib, or hepatitis B vaccines used concomitantly with IPOL vaccine, no interferences
have been observed on the immunological end points accepted for clinical protection. (11) (16)
(36) (See DRUG INTERACTIONS section.)
If the third dose of IPOL vaccine is given between 12 to 18 months of age, it may be desirable to
administer this dose with Measles, Mumps, and Rubella (MMR) vaccine and/or other vaccines
using separate syringes at separate sites, (28) but no data on the immunological interference
between IPOL vaccine and these vaccines exist.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 21 of 28
Use in Previously Vaccinated Children 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Children and adolescents with a previously incomplete series of polio vaccine should receive
sufficient additional doses of IPOL vaccine to complete the series.
Interruption of the recommended schedule with a delay between doses does not interfere with the
final immunity. There is no need to start the series over again, regardless of the time elapsed
between doses.
The need to routinely administer additional doses is unknown at this time. (28)
Adults
Unvaccinated Adults
A primary series of IPOL vaccine is recommended for unvaccinated adults at increased risk of
exposure to poliovirus. While the responses of adults to primary series have not been studied, the
recommended schedule for adults is two doses given at a 1 to 2 month interval and a third dose
given 6 to 12 months later. If less than 3 months but more than 2 months are available before
protection is needed, three doses of IPOL vaccine should be given at least 1 month apart.
Likewise, if only 1 or 2 months are available, two doses of IPOL vaccine should be given at least
1 month apart. If less than 1 month is available, a single dose of IPOL vaccine is recommended.
(28)
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 22 of 28
Incompletely Vaccinated Adults 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Adults who are at an increased risk of exposure to poliovirus and who have had at least one dose
of OPV, fewer than three doses of conventional IPV or a combination of conventional IPV or
OPV totaling fewer than three doses should receive at least one dose of IPOL vaccine. Additional
doses needed to complete a primary series should be given if time permits. (28)
Completely Vaccinated Adults
Adults who are at an increased risk of exposure to poliovirus and who have previously completed
a primary series with one or a combination of polio vaccines can be given a dose of IPOL vaccine.
The preferred injection site of IPOL vaccine for adults is in the deltoid area.
HOW SUPPLIED Syringe, without needle, 0.5 mL (10 per package) – NDC 49281-860-55.
Vial containing ten 0.5 mL doses - NDC 49281-860-10.
STORAGE The vaccine is stable if stored in the refrigerator at 2°C to 8°C (35°F to 46°F). The vaccine must
not be frozen.
Protect from light.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 23 of 28
REFERENCES 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
1 van Wezel AL, et al. Inactivated poliovirus vaccine: Current production methods and new
developments. Rev Infect Dis 6 (Suppl 2): S335-S340, 1984.
2 Montagnon BJ, et al. Industrial scale production of inactivated poliovirus vaccine prepared
by culture of Vero cells on microcarrier. Rev Infect Dis 6 (Suppl 2): S341-S344, 1984.
3 McBean AM, et al. Serologic response to oral polio vaccine and enhanced-potency
inactivated polio vaccines. Am J Epidemiol 128: 615-628, 1988.
4 Murdin AD, et al. Inactivated poliovirus vaccine: past and present experience. Vaccine 8:
735-746, 1996.
5 Sabin AB. Poliomyelitis. In Brande AI, Davis CE, Fierer J (eds) International Textbook of
Medicine, Vol II. Infectious Diseases and Medical Microbiology. 2nd ed. Philadelphia, WB
Saunders, 1986.
6 Prevots DR, et al. Vaccine-associated paralytic poliomyelitis in the United States, l980-
1994: current risk and potential impact of a proposed sequential schedule of IPV followed
by OPV (Abstract #H90). In: Abstracts of the 36th Interscience Conference on
Antimicrobial Agents and Chemotherapy. Washington, DC. American Society for
Microbiology, 179, 1996.
7 ACIP. Updated Recommendations of the Advisory Committee on Immunization Practices.
Poliomyelitis Prevention in the United States. MMWR 49: No. RR-5, 2000.
8 Salk J, et al. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose
regimen. Ann Clin Res 14: 204-212, 1982.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 24 of 28
9 Salk J, et al. Killed poliovirus antigen titration in humans. Develop Biol Standard 41: 119-
132, 1978.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
10 Salk J, et al. Theoretical and practical considerations in the application of killed poliovirus
vaccine for the control of paralytic poliomyelitis. Develop Biol Standard 47: 181-198, 1981.
11 Unpublished data available from Sanofi Pasteur SA.
12 Unpublished data available from Sanofi Pasteur Inc.
13 Faden H, et al. Comparative evaluation of immunization with live attenuated and enhanced
potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune
responses. J Infect Dis 162: 1291-1297, 1990.
14 Vidor E, et al. The place of DTP/eIPV vaccine in routine pædiatric vaccination. Rev Med
Virol 4: 261-277, 1994.
15 Bottiger M. Long-term immunity following vaccination with killed poliovirus vaccine in
Sweden, a country with no circulating poliovirus. Rev Infect Dis 6 (Suppl 2): S548-S551,
1984.
16 Plotkin SA, et al. Inactivated polio vaccine for the United States: a missed vaccination
opportunity. Pediatr Infect Dis J 14: 835-839, 1995.
17 Marine WM, et al. Limitation of fecal and pharyngeal poliovirus excretion in Salk-
vaccinated children. A family study during a Type 1 poliomyelitis epidemic. Amer J Hyg
76: 173-195, 1962.
18 Bottiger M, et al. Vaccination with attenuated Type 1 poliovirus, the Chat strain. II.
Transmission of virus in relation to age. Acta Paed Scand 55: 416-421, 1966.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 25 of 28
19 Dick GWA, et al. Vaccination against poliomyelitis with live virus vaccines. Effect of
previous Salk vaccination on virus excretion. Brit Med J 2: 266-269, 1961.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
20 Wehrle PF, et al. Transmission of poliovirus; III. Prevalence of polioviruses in pharyngeal
secretions of infected household contacts of patients with clinical disease. Pediatrics 27:
762-764, 1961.
21 Adenyi-Jones SC, et al. Systemic and local immune responses to enhanced-potency
inactivated poliovirus vaccine in premature and term infants. J Pediatr 120: No 5, 686-689,
1992.
22 Chin TDY. Immunity induced by inactivated poliovirus vaccine and excretion of virus. Rev
Infect Dis 6 (Suppl 2): S369-S370, 1984.
23 Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. Develop
Biol Standard 47: 247-255, 1981.
24 Bijerk H. Surveillance and control of poliomyelitis in the Netherlands. Rev Infect Dis 6
(Suppl 2): S451-S456, 1984.
25 Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis 6 (Suppl 2): S457-
S460, 1984.
26 Conyn van Spaendonck M, et al. Circulation of Poliovirus during the poliomyelitis outbreak
in the Netherlands in 1992-1993. Amer J Epidemiology 143: 929-935, 1996.
27 Strebel PM, et al. Epidemiology of poliomyelitis in the United States one decade after the
last reported case of indigenous wild virus associated disease. Clin Infect Dis 14: 568-579,
1992.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 26 of 28
28 ACIP. Poliomyelitis prevention in the United States: introduction of a sequential
vaccination schedule of Inactivated Poliovirus Vaccine followed by Oral Poliovirus
Vaccine. MMWR 46: No. RR-3, 1997.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
29 WHO. Weekly Epidemiology Record 54: 82-83, 1979.
30 Certification of poliomyelitis eradication - the Americas, 1994. MMWR 43: 720-722, 1994.
31 Institute of Medicine. An evaluation of poliomyelitis vaccine poliomyelitis vaccine policy
options. Washington, DC. National Academy of Sciences, 1988.
32 ACIP. Immunization of children infected with human T-lymphotropic virus type
III/lymphadenopathy-associated virus. MMWR 35: 595-606, 1986.
33 ACIP. General recommendations on immunization. MMWR 43: No. RR-1, 1994.
34 Barbi M, et al. Antibody response to inactivated polio vaccine (eIPV) in children born to
HIV positive mothers. Eur J Epidemiol 8: 211-216, 1992.
35 Varon D, et al. Response to hemophilic patients to poliovirus vaccination: Correlation with
HIV serology and with immunological parameters. J Med Virol 40: 91-95, 1993.
36 Vidor E, et al. Fifteen-years experience with vero-produced enhanced potency inactivated
poliovirus vaccine (eIPV). Ped Infect Dis J, 312-322, 1997.
37 Stratton, R. et al. Adverse Events Associated with Childhood Vaccines. Polio Vaccines.
National Academy Press, 295-299, 1994.
38 CDC. Vaccine Adverse Event Reporting System - United States. MMWR 39: 730-733,
1990.
39 CDC. National Childhood Vaccine Injury Act. Requirements for permanent vaccination
records and for reporting of selected events after vaccination. MMWR 37: 197-200, 1988.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 27 of 28
40 Food & Drug Administration. New Reporting Requirements for Vaccine Adverse Events.
FDA Drug Bull 18 (2), 16-18, 1988.
1
2
3
4
5
41 Recommended childhood immunization schedule - United States, 1999. MMWR 48: 12-16,
1999.
sanofi pasteur 15 October 2012 v 0.10 059 IPOL® LE 95503-0
Confidential/Proprietary Information Page 28 of 28
Product Information as of October 2012 1
2
3
4
5
6
7
8
9
10
11
12
13
14
Manufactured by:
Sanofi Pasteur SA
Lyon France
US Govt License #1724
Distributed by:
Sanofi Pasteur Inc.
Swiftwater PA 18370 USA
1-800-VACCINE (1-800-822-2463)
95503-0